Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by airflow limitation, in which inhaled bronchodilators play an essential part in disease control. Both long-acting muscarinic antagonists and long-acting β2- agonists are currently regarded as the key medications for patients with COPD. Indacaterol (IND) is the first ultra-long-acting β2-agonist bronchodilator that has been approved by the U.S. Food and Drug Administration in July 2011. This service provides a sensitive, simple and rapid capillary electrophoresis method for the simultaneous determination of indacaterol and glycopyrronium.